Priority Review Voucher Not For Sale, Alexion Says After Strensiq Approval
Executive Summary
Alexion plans to use voucher for one of its own products and might be targeting its next-generation version of blockbuster Soliris.
You may also be interested in...
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
The latest drug development news and highlights from our US FDA Performance Tracker.
Priority Review Vouchers Appear To Be Dropping In Price
Gilead spent less than $338m for the coupon entitling it to a speedier FDA review, down at least $12m from AbbVie's high-water purchase price almost a year ago.